Mm. Basade et al., ETOPOSIDE IN LANGERHANS CELL HISTIOCYTOSIS IN CHILDREN - A PRELIMINARY EXPERIENCE, Pediatric hematology and oncology, 13(2), 1996, pp. 159-162
Treatment of langerhans cell histiocytosis (LCH) is yet to be establis
hed. We treated seven patients with etoposide alone at a dose of 100 m
g/m(2)/day for 3 days given every 3 to 4 weeks for sir cycles. Three p
atients had received prior chemotherapy, two patients were less than 2
years of age, and two had liver dysfunction. A positive response to t
herapy was seen in five patients. There was no major toxicity. Etoposi
de therapy is safe and effective in the treatment of LCH.